196MO Anlotinib plus etoposide/carboplatin (EC) versus placebo plus EC in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): A randomized, double-blind, parallel controlled, phase III trial (ETER 701)

The overall survival (OS) improvement of immunochemotherapy in ES-SCLC is far from satisfactory. It is found that anlotinib (an anti-angiogenesis drug) could reprogram immunosuppressive tumor microenvironment and synergistic therapeutic benefits when combined with Immune checkpoint inhibitors and/or chemotherapy. ETER701 is the first randomized phase III trial evaluating anlotinib + etoposide/carboplatin (EC) ± benmelstobart (a novel developed PD-L1 inhibitor) vs placebo + EC in first-line ES-SCLC therapy.